Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK/Novartis Support For Benefiber Claims Too Thin To Convince NARB

This article was originally published in The Tan Sheet

Executive Summary

Referring to rather than providing two studies was GSK/Novartis' downfall in arguing before the National Advertising Review Board to support Benefiber regularity claims. GSK/Novartis questions the panel’s "refusal to accept the full translations of two confirmatory studies referred to in the record."

You may also be interested in...



Ingredient Studies Again Not Enough For New Nordic Product Claims – NAD

Two months after referring advertising for its Hair Volume supplement to FTC, NAD zeroes in on claims for New Nordic USA's Skin Care Collagen Filler supplement. NAD says the firm should discontinue anti-wrinkle and collagen-building claims in the absence of reliable evidence from well-controlled human clinical testing.

Kansas City TCM Firm Persists With COVID-19 Claims Following US Regulators' Warning

Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.

OTC Decisions In March: Lumify Single-Use, Aleve Arthritis-Grip Cap Labeling, And More Prilosec, Mucinex Copies

Total of CDER decisions during March on OTC applications was down from January and February and also were less substantial for the marketplace. After approving OTC switches in first two months, March decisions for newly available OTCs were limited to additional guaifenesin/pseudoephedrine and omeprazole products offered as private label/store brand alternatives to brands.

Topics

Related Companies

UsernamePublicRestriction

Register

PS108141

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel